<DOC>
	<DOCNO>NCT00864214</DOCNO>
	<brief_summary>Bioidentical compound hormone therapy ( BCHT ) consider 'safer ' option conventional hormone ( HT ) proponent . However , limited research data support claim . Our group Women 's Health Clinic , collaboration Departments Endocrinology , Complementary Medicine Laboratory Medicine , interested develop line research test safety efficacy BCHT . In present study , aim find dose BCHT bioequivalent conventional HT , randomize , blind , four-arm , phase I clinical trial . We estimate level estrone ( E1 ) , estradiol ( E2 ) estriol ( E3 ) baseline steady state two-weeks administration three commonly use dos bioidentical compound estrogen cream ( Biest ) standard dose conventional estrogen patch ( Vivelle-Dot ) . E1 , E2 , E3 value summarize use point estimate 95 % confidence interval . Two-sample t-test use compare Biest group Vivelle-Dot group . Healthy postmenopausal woman , contraindication hormone use , able fully understand participate trial , enrol . We utilize resource Mayo CRU conduct study .</brief_summary>
	<brief_title>A Pharmacokinetic Evaluation Bioidentical Compounded Estrogen Cream Natural Progesterone</brief_title>
	<detailed_description>This study design Phase I , blind , randomize , four-arm clinical trial . Participants randomize one four intervention : Biest transdermal cream 2.0 mg/0.5 g daily , Biest 2.5 mg/0.5 g daily , Biest 3.0 mg/0.5 g daily Vivelle-Dot patch 0.05 mg/24 hour change biweekly . Serum level E1 , E2 , E3 progesterone obtain baseline start intervention multiple time day 1 15 16 study , outline table ( Table 3.1 ) . The peak steady state concentration E1 , E2 E3 , along time reach peak level , area curve calculate . Baseline steady state level progesterone also compare compound micronized progesterone group . If abnormality estrogen level symptom suggest , vaginal ultrasound would do exclude possible ovarian activity source .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Women 4060 year old ; 2 . Postmenopausal status , document absence period ≥ 1 year amenorrhea ≥ 6 month along FSH ≥ 40 IU/L ; 3 . Surgical menopause ; 4 . History normal mammogram within last 11 month ; 5 . Normal screen lab ( within 20 % upper limit lab normal ) ; 6 . Able understand sign inform consent ; 7 . Able willing monitor CRU set provide blood sample request . 1 . Contraindications use hormones personal history coronary artery disease , stroke , breast cancer , DVT/PE , active liver gall bladder disease , hormone dependent migraine headache , endometrial , ovarian hormone dependent cancer ; 2 . Medical condition increase risk complication hormone replacement uncontrolled hypertension ( &gt; 160/100 mmHg ) , smoke , diabetes lupus ; 3 . Current use estrogen , progesterone testosterone ; Depending drug , could 7 day 6 month . 4 . Current use isoflavone containing product ; 5 . Current use protein bind medication like rifampin , warfarin , antiepileptic drug ( effect estrogen bioavailability ) ; 6 . Family history premenopausal breast cancer first degree relative , two premenopausal breast cancer second degree relative , male breast cancer , ovarian cancer two relative ; 7 . Women alcohol substance abuse dementia ( compliance issue ) . 8 . Women ten year last menstrual period ( unfavorable risk : benefit ratio ) 9 . Women peanut allergy ( Prometrium peanut oil ) 10 . Women find premenopausal estrogen level , confirm baseline Estradiol level &gt; 35 pg/ml vaginal ultrasound suggest ovarian activity .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>bioidentical hormone</keyword>
	<keyword>menopause</keyword>
	<keyword>estrogen</keyword>
	<keyword>progesterone</keyword>
</DOC>